<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970216</url>
  </required_header>
  <id_info>
    <org_study_id>PMST-Y-1</org_study_id>
    <nct_id>NCT00970216</nct_id>
  </id_info>
  <brief_title>Study of Telbivudine in Chronic Hepatitis B</brief_title>
  <official_title>A Prospective, Observational, Single-center Post-marketing Surveillance Study of Telbivudine in Chronic Hepatitis B Adults With HBeAg Positive/Negative.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and antiviral efficacy of
      telbivudine by maintained suppression of hepatitis B virus (HBV) DNA (&lt;=300 copies/ml or
      60IU/ml, undetectable by current polymerase chain reaction (PCR) - based assays) in HBeAg
      positive/negative patients at physician's general practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective: To evaluate the antiviral efficacy of telbivudine by maintained
      suppression of HBV DNA(&lt;=300 copies/ml or 60 IU/ml,undetectable by current PCR-based assays)
      in HBeAg positive patients from Week 24 to Week 48.

      Methodology: This will be an open-label, prospective, observational, single-center and single
      arm post marketing surveillance study.

      Number of patients: It is estimated to enroll 240 intent-to-treat patients in Taiwan.

      Population: Male or female patients, at least 18 years of age diagnosed with chronic
      hepatitis B with liver disease and telbivudine is prescribed by physicians based on clinical
      justification. And patients are able to communicate well, provide written informed consent,
      and willing to participate in the entire study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HBV-DNA &lt; 300 Copies/mL in 48 Weeks</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">160</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine</intervention_name>
    <description>Post-marketing observation for chronic hepatitis B patients receiving Telbivudine treatment</description>
    <other_name>Sebivo</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum will be stored at screening/baseline and complete study after corresponding with
      inclusion/exclusion criteria.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female patients, at least 18 years of age diagnosed with chronic hepatitis B with
        liver disease and telbivudine is prescribed by physicians based on clinical justification.
        And patients are able to communicate well, provide written informed consent, and willing to
        participate in the entire study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, at least 18 years of age.

          2. Documented chronic hepatitis B defined by all of the following:

               -  Clinical history compatible with chronic hepatitis B.

               -  Detectable serum hepatitis B surface antigen &gt;= 6 months at screening visit, with
                  either HBeAg positive or negative.

          3. Willing and able to comply with the observational drug regimen and all other study
             requirements.

          4. Willing and able to provide written informed consent to participate in the study.

        Exclusion Criteria:

          1. Females who are pregnant,intending to become pregnant or breast feeding.

          2. Patients with co-infection with hepatitis C virus, hepatitis D virus or human
             immunodeficiency virus.

          3. Patients with hypersensitivity to telbivudine or to any of the excipients.

          4. One or more known primary or secondary causes of liver disease other than hepatitis B
             (e.g., alcoholism, steatohepatitis, autoimmune hepatitis, hemochromatosis, alpha-1
             anti-trypsin deficiency, Wilson's disease, other congenital or metabolic conditions
             affecting the liver, congestive heart failure or other severe cardiopulmonary
             disease). Gilbert's syndrome and Dubin-Johnson syndrome will not exclude patients from
             participation in this trial.

          5. Enrolled or planning to be enrolled in another clinical trial of an investigational
             agent while participating in this study.

          6. Unable to receive safety and tolerability assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chau-ting Yeh, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>LinKou, Taoyuan County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2009</study_first_submitted>
  <study_first_submitted_qc>September 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2009</study_first_posted>
  <results_first_submitted>January 31, 2016</results_first_submitted>
  <results_first_submitted_qc>January 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 29, 2016</results_first_posted>
  <last_update_submitted>January 31, 2016</last_update_submitted>
  <last_update_submitted_qc>January 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBV DNA non-detectability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chronic Hepatitis B</title>
          <description>Patients with chronic hepatitis B, who received Telbivudine treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chronic Hepatitis B</title>
          <description>Patients with chronic hepatitis B, who received Telbivudine treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.9" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HBV-DNA &lt; 300 Copies/mL in 48 Weeks</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chronic Hepatitis B</title>
            <description>Patients with chronic hepatitis B, who received Telbivudine treatment</description>
          </group>
        </group_list>
        <measure>
          <title>HBV-DNA &lt; 300 Copies/mL in 48 Weeks</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Chronic Hepatitis B</title>
          <description>Patients with chronic hepatitis B, who received Telbivudine treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="45" subjects_affected="19" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever, mild</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle skeleton discomfort</sub_title>
                <counts group_id="E1" events="29" subjects_affected="18" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness and headache</sub_title>
                <counts group_id="E1" events="26" subjects_affected="12" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash and itching</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chau-Ting Yeh</name_or_title>
      <organization>Chang Gung Memorial Hospital</organization>
      <phone>88633281200 ext 8121</phone>
      <email>chautingy@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

